Recently, an interleukin-28 polymorphism has been acknowledged as powerful pretreatment predictor of SVR. 3, 4 Once treatment is initiated, the monitoring of ontreatment viral responses such as rapid virological response (RVR) and early virological response (EVR) can further aid in predicting treatment response. 5 However, there was little data evaluated the relationship between on-treatment ALT changes and therapeutic outcome of PegIFN and RBV in chronic HCV. Kim et al 6 reported interesting evidence
showing that the rapid normalization of serum ALT after start of treatment may play an additional role on predicting SVR.
Serum ALT levels are usually elevated in patients with chronic HCV, but more than half of patients may have a normal ALT level at some point due to its fluctuation. 7 In patients with persistently normal ALT levels, the median ALT levels remains stable for prolonged period, but transient elevations occur about 50% of cases. 8 Sustained normal serum ALT levels were associated with female, lower serum HCV RNA titer, and less inflammation and fibrosis on biopsy. 8 During chronic infection, serum HCV RNA levels remain relatively constant without significant fluctuation in untreated individuals. 9 This suggests that the process of viral production and clearance has been relatively balanced.
To investigate the effect ALT dynamics on SVR, we need to know the relationship with viral kinetics. Viral kinetic profiles show that the appearance of HCV RNA after initiation of standard therapy can be biphasic in the first 4 weeks. 10, 11 The final slope reflects the net loss of infected cells, and a rapid loss of infected cells is strongly associated with end treatment of response and SVR. 12, 13 Serum ALT, a surrogate marker of hepatocyte damage or death, decreases during antiviral treatment, and shows the lowest activity at the end of treatment. 14 The mechanism of decline of ALT level is not clear, but it can be explained by a reduction in infected cells, a non-cytolytic cure, or cell removal irrelevant ALT dynamics. However, a decreased ALT level at early phase of treatment is not related with apoptotic acitivity. 15 Theoretically, the rapid declines in ALT may reflect a rapid decrease of ongoing inflammation in the same manner as removal of the virus. The pattern of viral elimination shows a rapid decrease in the first month.
Ribeiro et al 14 showed that the RVR was significantly correlated the decline of ALT level at week 4 of treatment.
Also, the retrospective study of 111 patients with chronic HCV infection treated by conventional IFN and RBV demonstrated that larger decline rates of ALT within the first two and four weeks was predictors of SVR. 16 These correlations suggest that ALT dynamics can be presented a possibility to reflect rapid virological changes especially in patients with elevated baseline ALT levels. Because RVR is the most important predictor of SVR in genotype 2 or 3 infection, it is unreasonable to apply this result for predicting SVR except for genotype 1 infection.
Therefore, it is still unclear whether the use of serum ALT levels, instead of RVR, is helpful for predicting SVR in clinical practice.
In conclusion, this study showed that the rapid decline of ALT at week 4 of treatment is linked to SVR. To date, there is little data in relationship between ALT variability and SVR in chronic HCV infection. Therefore, such information predicting virological response may be useful to clinicians for designing a monitoring schedule, and counseling the future plan especially in patients with elevated baseline ALT levels and genotype 1 infection. Further well designed research is needed to test and confirm these concepts.
